Abstract
Objective. To analyze the relationship between allelic variants of angiogenesis factor genes and development of genital endometriosis (GE), its clinical evidence and treatment efficacy. Material and methods. 417 women with laparoscopically verified GE (main group) and 112 women without GE (control group) were examined. Among 358 women in both groups (251 with GE and 107 without GEregions of polymorphic angiogenesis factor genes G-1154A VEGF, 405C VEGF, T-604C KDR and G-735A Ang2 were identified by RFLP-analysis. Results. It has been established that carriage of separate polymorphic angiogenesis factor genes VEGF G-1154A (allele А and genotypes GA, АА) and G-405C (allele С and genotype GC), KDR T-604C (allele С and genotypes ТС and СС), Ang2 G-735A (allele А and genotypes СА and GА) and their combinations predispose to GE development in women of reproductive age. Carriage of genotype GA of polymorphism G-1154A of VEGF gene predisposes to the development of dysmenorrhea during GE. Pelvic pains and infertility during GE as well as efficacy of hormone treatment for these problems are not associated with carriage of separate polymorphisms of angiogenesis factor genes G-405C and G-1154A of VEGF gene, T-604C of KDR gene, G-735A of Ang2 gene. The most potent combination of polymorphisms of angiogenesis factor genes which predisposes to the development of GE is VEGF1154GА/KDRTС/Ang2АA, while VEGF1154АА/ KDRСС/Ang2GG combination predisposes to the development to endometriosis-associated infertility, and VEGF1154GG/KDRТC/Ang2AA combination predisposes to efficient treatment of infertility during GE. Conclusion. Polymorphic variants of angiogenesis factor genes G-1154A and 405C VEGF, T-604C KDR, G-735A Ang2 (separately or in their combinations) predispose to GE development. They are associated with its clinical evidence and treatment efficacy. For the formation of risk groups of GE development for primary prevention of GE and effective treatment of endometriosis-associated infertility it is advisable to identify combinations VEGF1154GА/KDRTС/Ang2АA, VEGF1154АА/KDRСС/Ang2GG, and VEGF1154GG/KDRТC/ Ang2AA of angiogenesis factors.
Highlights
It has been established that carriage of separate polymorphic angiogenesis factor genes VEGF G-1154A
their combinations predispose to genital endometriosis (GE) development in women
well as efficacy of hormone treatment for these problems are not associated with carriage of separate polymorphisms
Summary
Для цитирования: Кублинский К.С., Уразова О.И., Евтушенко И.Д., Куценко И.Г., Ковалева А.С. Связь аллельного полиморфизма генов ангиогенных факторов с развитием генитального эндометриоза, его клиническими проявлениями и эффективностью лечения. Проанализировать связь аллельных вариантов генов ангиогенных факторов с развитием генитального эндометриоза (ГЭ), его клиническими проявлениями и эффективностью лечения. Установлено, что носительство отдельных полиморфных генов факторов ангиогенеза VEGF G-1154A (аллеля А и генотипов GA, АА) и G-405C (С и генотипа GC), KDR T-604C (аллеля С и генотипов ТС и СС), Ang G-735A (аллеля А и генотипов СА и GА) и их комбинаций предрасполагает к развитию ГЭ у женщин репродуктивного возраста. Полиморфные варианты генов факторов ангиогенеза G-1154A и 405C VEGF, T-604C KDR, G-735A Ang (в отдельности или при их комбинации) предрасполагают к развитию ГЭ, ассоциированы с его клиническими проявлениями и эффективностью лечения. Для формирования групп риска развития ГЭ с целью первичной его профилактики и эффективного лечения эндометриоз-ассоциированного бесплодия целесообразно определение комбинаций факторов ангиогенеза VEGF1154GА/KDRTС/Ang2АA, VEGF1154АА/KDRСС/Ang2GG, VEGF1154GG/KDRТC/Ang2AA.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
